Ace and arb combination therapy for hypertension
Pro Research Analysisby 
Searched over 200M research papers
ACE and ARB Combination Therapy for Hypertension
Introduction to ACE and ARB Combination Therapy
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are commonly used in the management of hypertension. Combining these agents with other antihypertensive drugs, such as calcium channel blockers (CCBs), has been explored to enhance therapeutic outcomes. This article synthesizes current research on the efficacy and safety of ACE and ARB combination therapies for hypertension.
Efficacy of ACE/ARB and CCB Combination Therapy
Blood Pressure Reduction
Several studies have investigated the efficacy of combining ACE inhibitors or ARBs with CCBs. A meta-analysis involving 20,669 hypertensive patients from nine randomized controlled trials found that the combination of ACE/ARB with CCB (A+C) did not significantly differ in blood pressure (BP) reduction compared to other combination therapies . This finding was consistent across both systolic and diastolic BP measurements 19.
Cardiovascular Outcomes
Despite similar BP reduction, the A+C combination therapy demonstrated superior cardiovascular outcomes. The meta-analysis revealed a significantly lower incidence of cardiovascular composite endpoints, including cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke, compared to other combination therapies 19. This suggests that the A+C combination may offer additional cardiovascular protection beyond BP control.
Safety and Adverse Effects
General Safety Profile
The safety profile of ACE/ARB combination therapies has been a critical consideration. The same meta-analysis indicated that the incidence of adverse effects was similar between A+C therapy and other combinations 19. However, A+C therapy was associated with a significantly lower incidence of severe adverse effects 19.
Renal Function
The impact on renal function is another important aspect of combination therapy. The A+C combination was found to preserve renal function better, with a greater estimated glomerular filtration rate (eGFR) compared to other combinations 19. This renal protective effect is particularly beneficial for patients with coexisting renal conditions.
Special Populations: Black Patients with Hypertension
Efficacy in Black Patients
The efficacy of ACE inhibitors and ARBs in black patients has been debated. Studies indicate that black patients may have a reduced BP response to ACE inhibitors or ARBs when used as monotherapy . However, this reduced efficacy is not observed in combination therapies, suggesting that combining these agents with CCBs or thiazide diuretics is effective in this population .
Cardiovascular and Cerebrovascular Outcomes
Data on cardiovascular and cerebrovascular outcomes in black patients are conflicting. Some studies suggest increased morbidity and mortality with ACE inhibitor or ARB monotherapy, but these outcomes are not observed with combination therapy . Therefore, using ACE/ARB in combination with other agents is recommended for black patients to achieve better clinical outcomes.
Conclusion
Combining ACE inhibitors or ARBs with CCBs offers significant benefits in managing hypertension. While BP reduction is comparable to other combination therapies, the A+C combination provides superior cardiovascular protection and better preservation of renal function. This combination is also effective in black patients, who may not respond as well to monotherapy. Overall, ACE/ARB and CCB combination therapy is a valuable strategy in the comprehensive management of hypertension.
Sources and full results
Most relevant research papers on this topic